NovoCure, which markets a wearable electric field device for treating glioblastoma brain cancer, raised $165 million by offering 7.5 million shares (all primary) at $22, below the downwardly revised range of $23 to $24. The company originally planned to offer 12.5 million shares, including 5 million secondary shares, at $26 to $29. NovoCure plans to list on the Nasdaq under the symbol NVCR. J.P. Morgan, Deutsche Bank and Evercore Partners acted as lead managers on the deal.
The article NovoCure prices IPO at $22, below the downwardly revised range originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.